KR970705997A - N-{4-[2-(1, 2, 3, 4-테트라히드로-6, 7-디메톡시-2-이소퀴놀리닐)-에틸]-페닐}-9, 10-디히드로-5-메톡시-9-옥소-4-아크리딘 카르복사미드 화합물(gf120918a)을 포함하는 비경구 제약 조성물(parenteral pharmaceutical compositions containing gf120918a) - Google Patents

N-{4-[2-(1, 2, 3, 4-테트라히드로-6, 7-디메톡시-2-이소퀴놀리닐)-에틸]-페닐}-9, 10-디히드로-5-메톡시-9-옥소-4-아크리딘 카르복사미드 화합물(gf120918a)을 포함하는 비경구 제약 조성물(parenteral pharmaceutical compositions containing gf120918a)

Info

Publication number
KR970705997A
KR970705997A KR1019970702223A KR19970702223A KR970705997A KR 970705997 A KR970705997 A KR 970705997A KR 1019970702223 A KR1019970702223 A KR 1019970702223A KR 19970702223 A KR19970702223 A KR 19970702223A KR 970705997 A KR970705997 A KR 970705997A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
effective amount
group
safe
composition
Prior art date
Application number
KR1019970702223A
Other languages
English (en)
Korean (ko)
Inventor
웨이-킨 통
믹키 리 웰즈
Original Assignee
그래함 브레레톤
글락소 웰컴 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 그래함 브레레톤, 글락소 웰컴 인크. filed Critical 그래함 브레레톤
Publication of KR970705997A publication Critical patent/KR970705997A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1019970702223A 1994-10-05 1995-10-04 N-{4-[2-(1, 2, 3, 4-테트라히드로-6, 7-디메톡시-2-이소퀴놀리닐)-에틸]-페닐}-9, 10-디히드로-5-메톡시-9-옥소-4-아크리딘 카르복사미드 화합물(gf120918a)을 포함하는 비경구 제약 조성물(parenteral pharmaceutical compositions containing gf120918a) KR970705997A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31830894A 1994-10-05 1994-10-05
US08/318,308 1994-10-05
PCT/US1995/012952 WO1996011007A1 (en) 1994-10-05 1995-10-04 Parenteral pharmaceutical compositions containing gf120918a

Publications (1)

Publication Number Publication Date
KR970705997A true KR970705997A (ko) 1997-11-03

Family

ID=23237614

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702223A KR970705997A (ko) 1994-10-05 1995-10-04 N-{4-[2-(1, 2, 3, 4-테트라히드로-6, 7-디메톡시-2-이소퀴놀리닐)-에틸]-페닐}-9, 10-디히드로-5-메톡시-9-옥소-4-아크리딘 카르복사미드 화합물(gf120918a)을 포함하는 비경구 제약 조성물(parenteral pharmaceutical compositions containing gf120918a)

Country Status (12)

Country Link
EP (1) EP0784474A2 (pt)
JP (1) JPH10507177A (pt)
KR (1) KR970705997A (pt)
AU (1) AU702519B2 (pt)
BR (1) BR9509251A (pt)
CA (1) CA2201628A1 (pt)
CZ (1) CZ104197A3 (pt)
HU (1) HUT77883A (pt)
NZ (1) NZ295546A (pt)
PL (1) PL319511A1 (pt)
RU (1) RU2157687C2 (pt)
WO (1) WO1996011007A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
GB9710612D0 (en) * 1997-05-23 1997-07-16 Glaxo Group Ltd Synthesis of acridine derivatives
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
HUP0104280A3 (en) 1998-10-08 2002-07-29 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors, process for their preparation, medicaments containing them
AT408186B (de) * 1998-12-15 2001-09-25 Sanochemia Pharmazeutika Ag Wässerige zubereitung von beta-carotin
DE60045114D1 (de) 1999-05-17 2010-11-25 Cancer Res Ventures Ltd Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen
US6521635B1 (en) 2000-01-20 2003-02-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of MXR transport by acridine derivatives
ES2253398T3 (es) * 2000-06-30 2006-06-01 Inex Pharmaceuticals Corp. Camptotecinas liposomales mejoradas y sus usos.
WO2003002150A1 (en) * 2001-06-28 2003-01-09 Wyeth Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2783680B2 (ja) * 1991-01-11 1998-08-06 ラボラトワール、グラクソ、ソシエテ、アノニム アクリジン誘導体

Also Published As

Publication number Publication date
WO1996011007A1 (en) 1996-04-18
PL319511A1 (en) 1997-08-18
HUT77883A (hu) 1998-09-28
AU702519B2 (en) 1999-02-25
NZ295546A (en) 1999-01-28
CZ104197A3 (en) 1997-09-17
JPH10507177A (ja) 1998-07-14
AU3891395A (en) 1996-05-02
CA2201628A1 (en) 1996-04-18
MX9702473A (es) 1997-07-31
EP0784474A2 (en) 1997-07-23
BR9509251A (pt) 1997-10-21
RU2157687C2 (ru) 2000-10-20

Similar Documents

Publication Publication Date Title
US5725878A (en) Pharmaceutical composition comprising HIV protease inhibiting compounds
JP5348818B2 (ja) 無針注射用の安定な高濃度メロキシカム溶液
KR970705997A (ko) N-{4-[2-(1, 2, 3, 4-테트라히드로-6, 7-디메톡시-2-이소퀴놀리닐)-에틸]-페닐}-9, 10-디히드로-5-메톡시-9-옥소-4-아크리딘 카르복사미드 화합물(gf120918a)을 포함하는 비경구 제약 조성물(parenteral pharmaceutical compositions containing gf120918a)
PL318560A1 (en) Novel orally administered preparations containing cyclosporin of simple composition and high bioavailability
PL351259A1 (en) Composition containing testosterone undexanate and castor oil
BG106439A (en) Pharmaceutical composition of improved solubility and oral absorptivity, containing benzamide derivative
GB9907715D0 (en) Pharmaceutical compositions
JP2005002123A5 (pt)
KR20000068528A (ko) 4,5-에폭시모르피난 유도체를 함유하는 안정한 의약품 조성물
WO2009111057A4 (en) Fulvestrant formulations
KR970032859A (ko) 택산 조성물 및 이의 제조방법
DE69734017D1 (de) Arzneimittel zusammensetzungen und vorrichtungen zu deren verabreichung
RU2001129362A (ru) Композиция, включающая ундеканоат тестостерона и касторовое масло
KR970706021A (ko) N-치환-o-톨루이딘유도체로 이루어진 약용배합제 및 경피흡수형제제(MEDICINAL ADJUVANTS CONSISTIONG OF AN N-SUBSTITUED-o-TOLUIDING DERIVANTIVE, AND PERCUTANEOUSLY ABSORBALE PREPARATIONS COMPRISING THE ADJUVANTS)
AU708688B2 (en) Composition comprising mupirocin and chlorhexidine
RU97107466A (ru) Фармацевтические составы для парентерального введения, содержащие gf120918a
EA200100871A1 (ru) Кристаллическая форма эплеренона, обладающая повышенной скоростью растворения
AU707220B2 (en) Pharmaceutical composition for parenteral application containing an indole-carboxylic acid
MXPA04000535A (es) FORMULACIONES ANTIHISTAMINICAS PARA FORMAS DE DOSIFICACION DE CaPSULAS SUAVES.
EP0867181A1 (en) Nasal melatonin composition
US4760059A (en) Rectal dosage form
AU3941400A (en) Pharmaceutical composition
CN1164189A (zh) 含有gf120918a的非肠道药物组合物
RU99114888A (ru) Способ профилактики развития вторичной эндотелиально-эпителиальной дистрофии роговицы

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid